Oncology’s Fifth Pillar: Cellular Immunotherapy
An assay from Charles River Laboratories can improve the screening of CAR T cells, CAR natural killer cells, or cells carrying engineered TCRs for cell-based cancer immunotherapy.
Enzyme-Inhibitor May Open Door to New Therapies for Parasitic Diseases
First inhibitor of enzyme long thought to be potential drug target for fighting disease-causing parasites and bacteria is identified.
Regeneron, Adicet Partner to Research Engineered Immune-Cell Therapeutics
Collaboration aimed at generating multiple clinical product candidates for various blood and solid tumor cancers
Amicus Cuts Jobs, Overhauls GSK Collab, and Acquires Callidus
Biotech says actions will reposition the company as a top-tier ERT developer and save it $4 million annually.
Biogen Wins Full EC Approval for MS Drug Fampyra
Drug designed to improve walking in MS patients was granted conditional approval in the EC in 2011; full approval is based on data from the Phase III ENHANCE study
MD Anderson, Pfizer Launch Immuno-Oncology Collaboration
The University of Texas MD Anderson Cancer Center will join with Pfizer to study novel combinations of three of the pharma giant’s immuno-oncology candidates and other Pfizer treatments for solid and blood cancers
Cellmid Licenses Midkine Diagnostic Tech to Fujikura Kasei
Fujikura Kasei is exercising its previously agreed-upon option to license Cellmid’s midkine (MK) diagnostic technology, paying out a JPY 40 million (approximately $400,000) milestone fee.
Biogen, Vir to Partner on Manufacturing Antibodies to Treat COVID-19
Biogen will partner with Vir Biotechnology to advance the development and clinical manufacturing of Vir’s human monoclonal antibodies as potential treatments for COVID-19.
FucoID: Fast, Precise Tool Identifies Tumor-Targeting T Cells
A technique developed by researchers at Scripps Research seeks to identify useful tumor-infiltrating immune cells more quickly and precisely. The method, called FucoID, is named after the enzyme fucosyltransferase that "tags" the surface of sought-after immune cells so they can be seen and captured.
Sanofi Inks Autoimmune Collab That Could Mean $0.5B in Payments for...
ImmuNext entered into an agreement with Sanofi to develop a novel protein for the treatment of autoimmune disorders
